But if you've already been diagnosed with prostate cancer, you may need a different test-- for the prostate-specific membrane antigen or PSMA. PSA can show up in cells throughout the body ...

He remains symptom-free. The treatment is now approved for more patients. The randomized trial in 468 patients showed that 177 Lu-PSMA-617 prolonged progression-free survival (the period when the ...

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

The antibody 7E11 binds to the intracellular epitope of PSMA and can reach this only when the cell membrane is damaged. In this case, the tumor on the right was irradiated; the left one was not. The ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...

PSMA-targeted radioligand therapies (PRLT) for metastatic castration-resistant prostate cancer (mCRPC) decrease PSA levels and improve quality of life (QoL) with infrequent severe toxic events ...

The FDA has expanded Pluvicto's indication for PSMA-positive mCRPC patients post-ARPI therapy, delaying taxane-based chemotherapy. Selection for Pluvicto should be based on PSMA expression using ...